GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline (GSK) has announced the European Medicines Agency’s acceptance of their marketing application for Blenrep, a treatment for relapsed or refractory multiple myeloma. Promising results from two phase III trials, DREAMM-7 and DREAMM-8, indicated significant improvements in progression-free survival when compared to standard care. If approved, Blenrep could notably change the treatment landscape for this challenging blood cancer.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
